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1. Introduction  
Women have unique risk factors for cardiovascular diseases and cerebrovascular diseases 
such as pregnancy and hormone replacement therapy. Pregnancy provides an opportunity 
to reveal various cardiovascular disease risk factors and estimate a woman's lifetime risk 
because of its unique cardiovascular and metabolic stress. 
The causes of recurrent pregnancy loss (RPL) are classified as genetic, anatomic, 
endocrinologic, immunologic, microbiologic, environmental, and further more (Kutteh, 
1999; Christiansen et al., 2005). Several lines of study have suggested that certain 
coagulation abnormalities such as antiphospholipid antibodies or Factor V Leiden, the 
genetic defect underlying resistance to activated protein C, are causes of RPL (Kutteh, 1999). 
New diagnostic methods have improved the clinical triage of RPL (Kutteh, 1999; Li, 1998). 
Transvaginal pulsed Doppler ultrasonography allows noninvasive evaluation of uterine 
circulation. The introduction of pulsed Doppler ultrasonography has provided noninvasive 
means for the evaluation of uterine impedance, and gives physiologic data, rather than 
anatomic information alone. It is known that resistance to uterine arterial blood flow is 
associated with poor obstetrical outcome such as preeclampsia and fetal growth restriction 
(Nakatsuka et al, 1999b; Nakatsuka et al, 2002; Takata et al, 200). 
We have reported that impaired uterine perfusion is observed in a portion of women with 
RPL (Habara et al., 2002; Nakatsuka et al., 2003a, 2003b). Pulsed Doppler ultrasonography in 
the uterine artery may be useful in distinguishing women with RPL caused by vascular 
dysfunction from women with unexplained RPL (Habara et al., 2002). Furthermore, the 
plasma level of adrenomedullin, which is often associated with pathological processes of the 
vasculature (Hinson, 2000), is elevated in women with RPL (Nakatsuka et al., 2003a). 
However, vascular changes in women with RPL have not been fully elucidated. 
Antiphospholipid antibody syndrome (APS), which is an autoimmune disease associated 
with coagulopathy, is a well-known cause of RPL (Nakatsuka et al., 2003b). 
Antiphospholipid antibodies refer to several groups of autoantibodies with specificity for a 
number of negatively-charged phospholipids such as cardiolipin, phosphatidylserine, and 
phosphatidylethanolamine, or phospholipid-binding glycoproteins such as ǃ2 glycoprotein I 
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(ǃ2GPI) and prothrombin. There are currently data supporting an association between 
various types of antiphospholipid antibodies and vascular diseases (Nayak & Komatireddy 
et al., 2002). Previous studies suggest that predominantly IgG and to lesser extent IgM 
isotype of antiphospholipid antibodies and lupus anticoagulant (LAC) are associated with 
arterial and venous thrombosis, thrombocytopenia, and livedo reticularis (Nayak & 
Komatireddy et al., 2002). Anti-cardiolipin and anti-ǃ2GPI antibodies are elevated in 
patients with coronary artery disease. Anti-cardiolipin antibodies are also associated with 
typical chest pain, significant coronary artery stenosis on angiography and prediction of 
myocardial infarction (Sherer &Shoenfeld, 2003). 
Premature atherosclerosis is a clinical feature of thrombotic patients with primary APS 
(Ames et al., 2009). Early data from the Italian Antiphospholipid Registry calculated a 2.5% 
patient/year incidence of recurrent thrombosis often fatal; a prospective Spanish study 
demonstrated that 5.2% of primary APS patients died of recurrent arterial occlusions; Italian 
longitudinal study showed a 5.2% patient/year mortality rate for recurrent arterial 
thrombosis and a Russian group recently reported a 17% 8-year vascular mortality for 
primary APS (Ames et al., 2009). 
Polycystic ovary syndrome (PCOS) is one of the most common endocrinological disorders 
among reproductive-age women (Franks, 1995; Dunaif, 1997, The Rotterdam 
ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004). Using a combination of 
clinical, ultrasonographic, and biochemical criteria, the diagnosis of PCOS is usually 
reserved for those women who display one or more clinical symptoms including chronic 
anovulation, an ultrasonographical morphology of polycystic ovaries, inappropriate 
gonadotropin secretion, and hyperandrogenism (Franks, 1995; Dunaif, 1997). It is reported 
that women with PCOS have adverse pregnancy outcome including miscarriage (Abbott et 
al., 2002; Doldi et al., 1998; Glueck et al., 1999; Wang et al., 2001; Diejomaoh et al., 2003). 
We and the other researchers demonstrated an impaired uterine perfusion in women with 
PCOS (Ajossa et al., 2002; Chekir C et al., 2005). Abnormal sex steroid hormones have been 
suggested as the cause for the elevated blood flow resistance in the uterine artery of women 
with PCOS (Zaidi et al., 1998). Furthermore, risk factors for cardiovascular disease including 
central obesity, hyperandrogenism, hyperinsulinemia, and dyslipidemia, which are 
commonly observed in women with PCOS, may lead to impairment of uterine perfusion 
and vascular dysfunction (Slowinska-Srzednicka et al., 1991; Legro ,2003; Sabuncu et al., 
2001; Fenkci et al., 2003; Setji & Brown, 2007). 
In the light of these studies, vascular dysfunction may be the key to the pathophysiology of 
pregnancy loss. This chapter reviews association between RPL and vascular dysfunction.  
2. Impaired uterine arterial blood flow in women with RPL 
Pregnancy loss in LPS-treated rats is associated with coagulopathy, decreased placental 
blood flow, and placental and fetal hypoxia. This impairment in uteroplacental 
hemodynamics in LPS-treated rats is linked to increased uterine artery resistance (Graham 
et al., 2011). In Human, peripheral vascular resistance in normal pregnancy decreases as 
early as 5 weeks of gestation (Robson, 1989). Resistance in uterine arterial blood flow also 
exhibits a progressive decrease after implantation while it increases in women with 
preeclampsia or fetal growth restriction (Steel et al., 1990). Pulsed Doppler velocimetry of 
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the uterine artery has been reported to predict preeclampsia, fetal growth restriction, or 
gestational diabetes (van den Elzen et al., 1995). However, predictive value of uterine 
arterial pulsed Doppler velocimetry in pregnancy loss is controversial (van den Elzen et al., 
1993; Jauniaux, et al., 1994; Kurjak et al., 1994; Alcázar, 2000; Nakatsuka et al., 2003a).. 
2.1 Pregnant women with RPL associated with antiphospholipid antibodies 
We measured the resistance in the uterine arteries of 104 pregnant women with and without 
RPL at 4 to 5 weeks’ gestation and evaluated association of autoantibodies including 
antiphospholipid antibodies (Nakatsuka et al., 2003a). In this study, uterine arterial 
pulsatility index (PI) in the RPL group was significantly higher than that in the control 
group (Figure 1). Women with antiphospholipid antibodies had an elevated PI in the uterine 
artery, which is prominent in women with RPL (Table 1). Coagulopathy and vascular 
dysfunction caused by antiphospholipid antibodies may impair uterine perfusion. 
 
Fig. 1. Resistance in uterine arterial blood flow of women with recurrent pregnancy loss 
(Nakatsuka et al., 2003a). 
 
APA : Antiphospholipid antibodies,  
n.a.: not available, Student’s t-test* : p<0.007. 
(Nakatsuka et al., 2003a). 
Table 1. Antiphospholipid antibodies and pulsatility index in the uterine artery 
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Pregnancies complicated with hypertensive disorders and/or fetal growth restriction are 
known to be associated with a defective trophoblastic invasion. Antiphospholipid antibodies 
are known to interfere with syncytialization of the trophoblasts in early pregnancy and cause 
decidual vasculopathy, thrombosis, and placental infarction later in pregnancy. However, the 
elevation of uterine arterial PI that we observed is more likely to be associated with vascular 
dysfunction rather than impaired trophoblastic invasion. Trophoblastic invasion affects little 
on uterine arterial blood flow at 4-5 weeks of gestation because decrease in blood flow 
resistance in the uterine artery is very slow until 8 weeks of gestation (Dickey et al., 1995). 
Pregnant women with antiphospholipid antibodies have vascular dysfunctions in the 
uterine artery although the prediction of adverse pregnancy outcome is not conclusive 
(Caruso et al, 1993; Venkat-Raman et al, 2001; Nakatsuka et al., 2003a). 
Interestingly, the uterine arterial PI in RPL women without antiphospholipid antibodies is 
significantly higher than that in the control pregnant women even among women without 
antiphospholipid antibodies in our study (Nakatsuka et al., 2003a). 
2.2 Non-pregnant women with unexplained RPL 
Pulsed Doppler ultrasonography demonstrated blood flow changes in the uterus and 
ovaries during the menstrual cycle (Goswamy and Steptoe, 1988a; Chekir et al., 2005). The 
uterine arterial PI has been known to diminish progressively during the luteal phase, during 
which implantation occurs. Differences in uterine blood flow impedance between fertile and 
infertile women (Goswamy et al., 1988b; Steer et al., 1994). Based on studies from the IVF-ET 
programme, impedance of blood flow through the uterine arteries is a good indicator of the 
probability of subsequent pregnancy (Salle et al., 1998). 
We investigated whether women with unexplained RPL have impaired uterine perfusion in 
the mid-luteal phase of non-conception cycles (Habara et al., 2002). The uterine arterial PI of 
121 women including 49 women with unexplained RPL was measured by transvaginal 
pulsed Doppler ultrasonography. The uterine artery PI in RPL group (2.54±0.45, mean 
±S.D.) was significantly higher than that in the control group (2.20±0.35). In the RPL group, 
the PI in the uterine artery of women with antinuclear antibodies (ANA) was significantly 
higher than that of women without ANA (Figure 2). There is no significant difference 
between the PI in the uterine artery of women with ANA and that of women without ANA 
in control group. Among women without ANA, the uterine artery PI in RPL group was also 
significantly higher than that in the control group. 
Although ANA are not specific pathogens for pregnancy loss (Ogasawara, et al., 1996), 
women with positive ANA may have other autoimmune antibodies causing vasculopathy 
or coagulopathy. These pathological changes are likely to cause elevation of the uterine 
arterial blood flow resistance and lead to RPL, early onset preeclampsia, or fetal growth 
restriction. Although the apparent underlying pathophysiology of these cases was not 
elucidated, they may have subclinical vasculopathy, which was not diagnosed by routine 
screening tests for RPL. 
2.3 Women with PCOS 
Relatively high rate of pregnancy loss has been reported in women with PCOS. We 
performed a pulsed Doppler study on uterine arterial blood flow in 25 women with PCOS 
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and 45 control women with regular menstrual cycles (Chekir et al.,2005). Among the control 
group, the uterine arterial PI in the luteal phase was significantly lower than that in the 
follicular phase (Figure 3). Among women with PCOS, the uterine arterial PI in the luteal 
phase tended to be lower than that in the follicular phase. The PI in the uterine artery in 
women with PCOS was significantly higher than that for the control group both in the 
follicular phase and in the luteal phase. Among women with PCOS, women with 
amenorrhea had a significantly higher uterine arterial PI than that of women with 
oligomenorrhea. 
 
Fig. 2. Pulsatility index in the uterine artery of women with or without antinuclear antibodies 
in control or RPL group. Bars, Mean. Values are expressed as mean ±S.D. (Habara et al., 2002) 
 
Fig. 3. Pulsatility index in the uterine artery in control women and women with PCOS. 
Left panel: Uterine arterial PI in control women. Data from control women during the 
follicular phase and the luteal phase are indicated by open circles. Right panel: Uterine 
arterial PI in women with PCOS. Data from women with amenorrhea during the follicular 
phase are indicated by closed circles. Data from women with oligomenorrhea during the 
follicular phase and the luteal phase are indicated by open circles (Chekir et al, 2005). 
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The uterine arterial PI was correlated with body mass index, luteinizing hormone /follicle-
stimulating hormone ratio, or low-density lipoprotein-cholesterol (LDL-C)/high-density 
lipoprotein-cholesterol (HDL-C) ratio while it was inversely correlated with the HDL-C 
level. 
3. Biomarkers for cardiovascular risk assessment in women with RPL 
The introduction of pulsed Doppler ultrasonography has provided the means for the 
noninvasive evaluation of uterine impedance, thus providing physiologic data on 
hemodynamic abnormalities in early pregnancy failures. Are these vascular changes in 
women with PRL observed solely in the uterine artery? Biomarkers for cardiovascular risk 
assessment are substances that are released into the blood when the vasculature is damaged. 
Some biomarkers cause vascular dysfunction directly or indirectly. It may be worth 
measuring biomarkers for cardiovascular risk assessment in women with RPL. 
3.1 Thrombomodulin 
Thrombomodulin binds thrombin, changes thrombin conformation and allows thrombin to 
activate protein C, which inhibits coagulation and thrombin-activatable fibrinolysis inhibitor, 
which inhibits fibrinolysis. Increased serum thrombomodulin, cleaved products of cellular 
thrombomodulin, has been demonstrated previously in preeclampsia (Dusse et al., 2011). 
Endothelial thrombomodulin is known to be a major vasoprotective molecule. However, 
elevated serum thrombomodulin is also likely to be a response to vascular activation.  
We measured serum levels of soluble thrombomodulin of 54 pregnant women at 4-8 weeks 
of gestation (Nakatsuka et al., 2004). Serum thrombomodulin was significantly elevated in 
women with antiphospholipid antibodies in RPL group compared with control women and 
with RPL women without antiphospholipid antibodies. Among women with APS, serum 
thrombomodulin in women who subsequently had a growth-restricted fetus had been 
significantly higher than that in women who subsequently had an appropriate-for-date 
fetus. Elevation of thrombomodulin is likely to indicate impaired uterine blood flow in 
women with RPL. 
It is controversial whether the soluble thrombomodulin level is an independent risk factor 
for coronary heart disease (Wu, 2003; Huang et al., 2008; Karakas et al., 2011). However, 
anti-cardiolipin antibodies are reported to be important not only in the pathogenesis of 
mixed connective tissue disease (MCTD) but in the induction of endothelial cell causing 
elevation of soluble thrombomodulin, and may play crucial roles in the development of 
early atherosclerosis in MCTD (Soltesz, 2010). It is also known that development of 
atherosclerosis and elevation of soluble thrombomodulin in serum of systemic lupus 
erythematosus (SLE) patients with metabolic syndrome (Mok et al., 2010). 
3.2 Adrenomedullin 
Adrenomedullin, a 52-amino acids-ringed, structured peptide, mediates vasodilatory 
properties through the second messenger cyclic adenosine, 3,5-monophosphate (Jougasaki 
& Burnett, 2000). The main source of plasma adrenomedullin is considered to be vascular 
endothelial cells and vascular smooth muscle cells. 
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Adrenomedullin has interaction with various bioactive molecules including nitric oxide, 
prostaglandins, atrial natriuretic peptide, renin, aldosterone, norepinephrine, arginine 
vasopressin, endothelin-1, and adrenocorticotropic hormone (Jougasaki & Burnett, 2000). 
The plasma level of adrenomedullin is elevated in various diseases including hypertension, 
diabetes, cardiac failure, septic shock, or SLE, which are often associated with pathologic 
processes of the vasculature (Jougasaki & Burnett, 2000; Hinson et al., 2000). 
We measured plasma levels of adrenomedullin of 100 pregnant women in the midluteal 
phase of a nonpregnant cycle (Nakatsuka et al., 2003b). We also measured the PI in the 
uterine arteries by transvaginal pulsed Doppler ultrasonography at the same time. The 
plasma level of adrenomedullin in women with RPL was significantly higher than that in 
control women. Uterine arterial PI of women with RPL was significantly higher than that in 
control women. Plasma level of adrenomedullin had a significant positive correlation with 
uterine arterial PI both in the control group (r=0.58, p < 0.001) and in the RPL group (r=0.78, 
p < 0.001) (Figure 4). Both plasma adrenomedullin concentration and uterine arterial PI were 
significantly high in women with antiphospholipid antibodies. 
 
Fig. 4. Plasma adrenomedullin and uterine arterial pulsatility index.  
A) Plasma adrenomedullin concentration and uterine arterial pulsatility index in control 
women. A significant positive correlation was determined by Pearson correlation coefficient 
(r =0.58, p<0.001). B) Plasma adrenomedullin concentration and uterine arterial pulsatility 
index in women with recurrent pregnancy loss. A significant positive correlation was 
determined by Pearson correlation coefficient (r =0.78,p <0.001). (Nakatsuka et al., 2003b) 
Increased plasma adrenomedullin in women with RPL is likely to be a response to vascular 
damage and increased vascular tone. Plasma adrenomedullin levels observed in women 
with recurrent pregnancy loss were similar to the values reported in patients with 
hypertension, mitral stenosis, primary aldosteronism, or SLE (Nakatsuka et al., 2003b).  
Although the pathophysiologic roles of adrenomedullin in RPL have not been fully 
elucidated, this peptide may serve as a biochemical marker to identify women with 
impaired uterine perfusion (Nakatsuka et al., 2003b; Ashraf et al., 2011) and also impaired 
systemic vasculatures. 
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3.3 The other markers associated with cardiovascular diseases 
We have previously reported that there is no significant difference in serum nitric oxide 
metabolite level between control women and women with recurrent pregnancy loss (Habara 
et al., 2002). However, anti-cardiolipin antibodies induce nitric oxide and superoxide 
production from vascular vessels, resulting in enhanced local levels of plasma peroxynitrite 
(Alves & Grima, 2003), which is a powerful pro-oxidant molecule (Nakatsuka et al, 1999). 
These oxidative damages in the cardiovascular system may be involved in atherosclerosis.  
PCOS has deserved major attention because it is linked to the same cluster of events that 
promote the metabolic syndrome. We have reported that women with PCOS had significantly 
higher total cholesterol, triglyceride, and β-lipoprotein levels than those of the control group. 
Significantly lower HDL-C, higher LDL-C, and consequently a higher LDL-C/HDL-C ratio 
were observed in women with PCOS as compared to those of the control women. Fasting 
serum insulin and homeostasis model assessment-R (HOMA-R), which are indexes of insulin 
resistance, in women with PCOS were significantly higher than those for the control group. 
It has been reported that isolated adipocytes from women with PCOS express higher mRNA 
concentrations of some adipokines involved in cardiovascular risk and insulin resistance 
(Garruti et al., 2009). The actions of adipokines and adipocytokines on platelets and vascular 
smooth muscle cells, both of which are deeply involved in atherothrombosis, have been 
reported (Anfossi et al, 2010). Adipose tissue from individuals with central obesity 
synthesizes and releases increased amount of proinflammatory chemokines and cytokines, 
such as monocyte chemoattractant protein-1 (MCP-1), macrophage migration inhibitory 
factor (MIF), tumor necrosis factor-ǂ (TNF-ǂ), and interleukins, including interleukin-1ǃ (IL-
1ǃ) and interleukin-6 (IL-6); procoagulant and proinflammatory mediators such as tissue 
factor (TF) and plasminogen activator inhibitor-1 (PAI-1); vasoactive substances such as 
angiotensinogen and endothelin-1 (ET-1); molecules involved in the pathogenesis of insulin 
resistance, such as TNF-ǂ and resistin (Anfossi et al, 2010). Elevated levels of PAI-1, the 
major natural antifibrinolytic agent, are involved in atherothrombosis in women with PCOS 
(Ehrmann, 2005). Women with RPL, who are characterized as PCOS might be monitored by 
measuring these bioactive molecules to predict development of cardiovascular diseases. 
4. Arterial stiffness in women with RPL 
Impaired uterine arterial blood flow and elevated cardiovascular disease risk markers 
suggest that early changes of systemic vasculature may be progressing in women with RPL. 
These changes lead to athrosclerosis and atherothrombosis and may cause coronary heart 
disease and/or stroke.  
4.1 Evaluation methods of arterial stiffness 
Reductions in the elasticity of central arteries may act as a marker of early changes that 
predispose to the development of major vascular disease. Arterial stiffness has been known 
as a major contributory factor to cardiovascular morbidity and mortality in patients with 
hypertension. Independent studies have shown that central arterial stiffness is increased in 
older individuals and in those with coronary artery disease, myocardial infarction, heart 
failure, hypertension, stroke, diabetes mellitus, end-stage renal disease, 
hypercholesterolemia, and inflammation (Nichols, 2005). 
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There are various methods in evaluation of atherosclerosis. Intima media thickness (IMT) of 
carotid arteries is used to evaluate early atherosclerosis and the risk of associated 
cardiovascular disease (Burke, et al., 1995). The The ankle-brachial index (ABI) for each leg 
was calculated as the ratio of the systolic pressures in the leg and the systolic pressure of 
either the left or right arm. An ABI < 1.0 in either leg was considered abnormal, suggesting 
peripheral arterial disease; progressively lower ABI values indicate more severe obstruction 
(Sacks et al., 2002). 
Pulse wave velocity (PWV) and the augmentation index (AI) are widely used as arterial 
stiffness indices. Recently, brachial-ankle PWV (baPWV) measurement can be performed 
easily by simultaneous oscillometric measurement of pulse waves in all four extremities. 
Brachial-ankle PWV was used as a substitute for aortic PWV because baPWV is known to be 
strongly correlated with aortic PWV (Matsui et al., 2004). PWV are known to be a marker of 
both the severity of vascular damage and the prognosis of atherosclerotic vascular diseases 
in patients with hypertension (Blacher et al., 1999), end-stage renal failure (London & Cohn, 
2002), and diabetes (Yokoyama et al., 2003). Increased PWV is known to be an independent 
predictor of the prognosis in hypertension, including in subjects under anti-hypertensive 
medication (Laurent et al., 2001). 
Carotid AI (cAI) was assessed by the proportion of the central pulse pressure resulting from 
peripheral arterial wave reflection. The AI is known to be an independent predictor of all-
cause and cardiovascular mortality in end-stage renal failure patients (London et al., 2001). 
It has been also reported that increased AI is associated with the presence and severity of 
coronary artery disease, particularly in younger and middle-aged male patients (Weber et 
al., 2004). Although PWV and AI have been known to be useful indices of atherosclerotic 
vascular diseases, data in young females are scarce. 
4.2 Women with PRL associated with antiphospholipid antibodies 
Antiphospholipid antibodies is known to play a central role in both pregnancy loss and 
cardiovascular diseases (Mackworth-Young, 2004). Antiphospholipid antibodies is a risk 
factor for incident stroke, however, the evidence to support the role of antiphospholipid 
antibodies in recurrent stroke is conflicting (Brey, 2004). Neither anti-cardiolipin antibodies 
nor anti-ǃ2GPI antibodies is reported to be associated with atherosclerosis in 
premenopausal women with APS and SLE, who have an increased prevalence of carotid 
and femoral plaque (Vlachoyiannopoulos et al., 2003). Furthermore, previous studies have 
paradoxically proposed a beneficial role for some antiphospholipid antibodies in 
atherosclerosis (Nicolo & Monestier, 2004). 
We assessed arterial stiffness of 153 women with RPL and 66 healthy women with one or 
less pregnancy loss. It is reported that abnormal ABIs are more common in primary APS 
than in healthy controls (Baron et al., 2005). However, we did not observe significant 
difference in ABI value or incidence of abnormal ABI between RPL women with 
antiphospholipid antibodies and control women. More sensitive methods may be necessary to 
detect early changes of vascular system in younger patients with antiphospholipid antibodies.  
Women with RPL had significantly higher baPWV than control women (Figure 5). Mean 
value of baPWV of RPL women with antiphospholipid antibodies is significantly higher 
than that in control women. None in control women or women with unexplained RPL 
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showed abnormal baPWV while five in RPL women with antiphospholipid antibodies 
showed abnormal baPWV (baPWV > 1,400 m/sec, American Heart Association 
Medical/Scientific Statement, 1993). Women with RPL had significantly higher cAI (22.5 ± 
171.2 %) than control women (-67.3 ± 151.7 %) (p<0.0005). Mean value of cAI of women with 
unexplained RPL or that of RPL women with antiphospholipid antibodies is significantly 
higher than that in control women (Figure 6). 
 
Fig. 5. baPWV of women with RPL   
  
Fig. 6. cAI of women with RPL 
4.3 Types of autoimmune antibodies and arterial stiffness in women with RPL 
Antiphospholipid antibodies are a heterogeneous group of autoantibodies directed against 
phospholipid binding proteins, such as anti-cardiolipin antibodies, anti-ǃ2GPI antibodies, 
and anti-phosphatidylserine/prothrombin antibodies, lupus anticoagulant, anti-
phosphatidylserine antibodies and anti-phosphatidylethanolamine antibodies. Pathogenesis 
of antiphospholipid antibodies may vary depending on types and target phospholipid. 
There is an increasing interest in clinical significance of various types of antiphospholipid 
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antibodies to define the patient’s risk of arterial and venous thrombosis (Galli et al., 2005) 
although it is inconclusive. 
Petri have reported that twenty years after diagnosis, SLE patients with lupus anticoagulant 
have a 50% chance of a venous thrombotic event and myocardial infarction occurs 
significantly more often (22%) in those with lupus anticoagulant (Petri, 2004). However, 
neither anti-cardiolipin nor lupus anticoagulant is associated with an increase of carotid 
IMT, carotid plaque, nor coronary calcium by helical CT, which are signs of subclinical 
atherosclerosis (Petri, 2004). In our study, we could not find any significant differences in 
baPWV or cAI between women with lupus anticoagulant and control women (Figure 7). 
 
*:p<0.05 vs. Control, aǃ2GPI: anti-ǃ2GPI antibodies, aCL: anti-cardiolipin antibodies, LAC:  
lupus anticoagulant, aPS: anti-phosphatidylserine antibodies, aPS/PT: antibodies against 
phosphatidylserine/prothrombin complex, K(-)aPE: kininogen independent anti 
phosphatidylethanolamine antibodies, K(+)aPE: kininogen dependent anti-phosphatidylethanolamine 
antibodies 
Fig. 7. cAI among women with various types of APA 
There is some evidence that high anti-ǃ2GPI antibodies can present a risk factor for 
atherosclerosis, but more epidemiological data are required in order to confirm whether the 
pro-atherogenic properties of anti-phospholipid antibodies signifies an independent risk 
factor for atherosclerosis and its complications. We observed that women with anti-ǃ2GPI 
antibodies had high cAI. Unfortunately, we could not perform statistical analysis because 
women with anti-ǃ2GPI antibodies were small population. 
It has been reported that a significantly high prevalence of anti-phosphatidylserine IgG was 
found in stroke patients (57.7%) (Kahles et al., 2005). Anti-phosphatidylserine antibodies 
have a strong predictive value and association for arterial thrombosis (Lopez et al., 2004). 
Antibodies against phosphatidylserine/prothrombin complex have been reported to be closely 
associated with clinical features of APS rather than antibodies against prothrombin alone 
(Atsumi et al., 2004). However, there are no reports on atherosclerosis in women with these 
antibodies. We observed no significant association between anti-phosphatidylserine antibodies 
or antibodies against phosphatidylserine-prothrombin complex and arterial stiffness. 
Recent studies have shown that some patients with unexplained thrombophilic disorders may 
have anti-phosphatidylethanolamine antibodies as the sole basis for their hypercoagulable 
**
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state (Sanmarco, et al., 2001). It is noteworthy that anti-phosphatidylethanolamine antibodies 
have been described as the sole antiphospholipid antibodies in patients with thrombotic 
diseases (Staub, et al., 1989; Karmochkine, et al., 1992; Berard, et al., 1996). However, there are 
little studies on association of anti-phosphatidylethanolamine antibodies and arterial stiffness 
or atherosclerosis. 
We observed that cAI was significantly increased in RPL women with anti-
phosphatidylethanolamine antibodies. Anti-phosphatidylethanolamine antibodies may be a 
risk factor for atherosclerosis in women with RPL. It has been reported that kininogen-
dependent IgG anti-phosphatidylethanolamine antibodies markedly increases thrombin-
induced platelet aggregation in vitro while kininogen independent IgG anti-
phosphatidylethanolamine antibodies do not augment thrombin-induced platelet 
aggregation (Sugi et al, 1999). However, we observed that both two types of anti-
phosphatidylethanolamine antibodies were associated with arterial stiffness. 
Physical distribution of phosphatidylethanolamine is known to be at the blood-endothelium 
interface. The luminal phosphatidylethanolamine is a vulnerable to anti- 
phosphatidylethanolamine autoimmunity, which is consistent with the association between 
anti- phosphatidylethanolamine antibodies and elevated risk for idiopathic thrombosis 
(Zhixin et al., 2011). 
Risk factors for atherosclerosis in SLE include traditional risk factors (mainly the 
Framingham risk factors). Moreover, specific antibodies to ǃ2GPI; anticardiolipin 
antibodies; anti-oxidized low-density lipoprotein (oxLDL); and antibodies to heat shock 
proteins may be cardiovascular disease risk factors (Sherer et al., 2010). Immune complexes 
containing oxLDL, ǃ2GPI, and/or CRP are known to be involved in atherosclerosis 
(Matsuura et al., 2006, Chekir et al, 2009). Autoantibodies to oxLDL/ǃ2GPI complex were 
detected in SLE and APS patients, and were strongly associated with arterial thrombosis 
(Christodoulou et al., 2007). Further studies may help evaluating clinical usefullness of these 
autoimmune antibodies involving in progression of atherosclerosis in women RPL. 
4.4 Women with PCOS 
Previous study on arterial stiffness has shown that both baPWV and cAI are useful for risk 
stratification of hypertensive patients (Matsui et al., 2004). In this study, both of these 
indices are significantly correlated with age and systolic blood pressure and cAI is reported 
to be correlated with total cholesterol and LDL-C in hypertensive patients. 
We have reported that women with PCOS in reproductive age have a significantly higher 
baPWV than that for the control women (Sasaki et al., 2011). Arterial stiffness evaluated 
using the baPWV and cAI in mildly-hypertensive women (systolic blood pressure ≥ 120 
mmHg or diastolic blood pressure ≥ 90 mmHg) with PCOS was significantly higher than 
that in the control women or normotensive women with PCOS. Early changes in vascular 
function were detected in mildly-hypertensive women with PCOS. 
4.5 Women with unexplained RPL 
We observed that women with unexplained RPL showed increased baPWV and cAI in 
average as compared with control women (Figure 5, 6). Although ranges of these indices in 
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women with unexplained RPL and those in control women were overlapped, at least a 
portion of women with unexplained RPL showed increased baPWV and cAI. These 
observations suggest that antiphospholipid antibodies or endocrinological disorders may 
not be the sole cause for arterial stiffness in women with RPL. Vascular dysfunction caused 
by various factors may be involved in at least a portion of women with unexplained RPL. 
A portion of women with unexplained RPL should be considered as a high risk group for 
atherosclerosis and cardiovascular diseases. Measurement of baPWV or AI is a promising 
technique to assess vascular dysfunction in women with RPL. 
5. Possible cardiovascular diseases in pregnant women with RPL 
In pregnant women with RPL, who have early changes of systemic vasculatures, may suffer 
vascular complications during pregnancy because of physiological hypercoagulability and 
hemodynamic changes associated with pregnancy. 
5.1 Venous thromboembolism (VTE) 
Thrombophilia is a risk factor for venous thromboembolism (VTE) in pregnancy because of 
the hypercoagulability of pregnancy, which is further increased in the presence of 
thrombophilia. Vascular reactivity, which is believed to be increased during pregnancy, may 
also compound the risk. 
Pregnant women are at increased risk of venous thromboembolism (VTE). Estimated 
incidence of VTE during pregnancy is about 1 event per 1000 pregnancies (Chauleur et al., 
2007). Despite this low incidence, thromboembolic complications occurring during 
pregnancy and post-partum remain a major cause of maternal death. Although pregnant 
women have a higher risk of developing thromboembolic complications than non-pregnant 
women, treating all pregnant women to prevent these events is not recommended. 
A scoring system for VTE risk in pregnant women (Chauleur et al., 2007) includes 
antiphospholipid antibodies and reproductive history of one stillbirth or at least three 
recurrent miscarriages, which are clinical features of women with APS (Bobba et al., 2007). 
5.2 Coronary heart disease and stroke in pregnancy 
The risk of acute myocardial infarction is known to be approximately 3 to 4 times higher in 
pregnancy. The incidence of pregnancy-related acute myocardial infarction is in the broad 
range of 3 to 10 per 100 000 deliveries that has been reported previously (James et al., 2006). 
Hypertension (odds ratio (OR) 21.7), thrombophilia including history of thrombosis and 
APS (OR 22.3), diabetes mellitus (OR 3.6), smoking (OR 8.4), transfusion (OR 5.1), 
postpartum infection (OR 3.2), and age 30 years and older remain as significant risk factors 
for pregnancy-related acute myocardial infarction in the multivariable analysis (James et al., 
2006). The odds of acute myocardial infarction are 30-fold higher for women aged 40 years 
and older than for women 20 years of age. 
Thrombophilia, gestational diabetes mellitus associated with PCOS, or age 30 years and 
older may increase the risk further in women with RPL. 
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There are few data on the risk of stroke in relation to the full range of outcomes of 
pregnancy (spontaneous or induced abortion, stillbirth, and live birth) (Kittner & Stern, 
1996). One of the most important risks factors for stroke is advanced maternal age, which 
suggests arterial stiffness and atherosclerosis may affect on the incidence of stroke (Bushnell, 
2008). The majority (48%) of pregnancy-related strokes occur in the postpartum period, 
versus 41% at delivery, and 11% antepartum (James et al., 2005). The Baltimore Washington 
Cooperative Young Stroke Study found that stroke rate was not increased in pregnant 
compared with nonpregnant women, but during the postpartum period, there was a 
fivefold increased risk of ischemic stroke (Kittner et al., 1996). Risk factors found to be 
associated with pregnancy-related stroke in the most recent analysis include thrombophilia 
(OR 16.0) and lupus (OR 15.2) (James et al., 2005). Preeclampsia and gestational 
hypertension, which are sometimes observed in women with RPL even during treatments, 
increase the risk of stroke during pregnancy as a result of severe hypertension and 
disturbed cerebral autoregulation. 
6. Reproductive history and cardiovascular disease risk later in life 
Adverse reproductive history and complications during pregnancy in women with RPL 
should to be considered as cardiovascular risk factors later in life. Physiological 
hypercoagulability, hemodynamic changes, and metabolic syndrome during pregnancy may 
provoke pregnancy complications including pregnancy loss, preeclampsia, placental 
abruption, preterm birth, or birth of an infant small for gestational age, or gestational 
diabetes mellitus in women with subclinical thrombophilia such as antiphospholipid 
antibodies or Factor V Leiden and/or subclinical endcrinological abnormalities such or 
PCOS. They could be considered a “failed stress test,” possibly unmasking early or 
preexisting endothelial dysfunction and vascular or metabolic disease (Mosca, 2011). 
6.1 Parity 
Endothelial function is improved and asymmetrical dimethylarginine, an endogenous nitric 
oxide synthase inhibitor, decreased during pregnancy, both of which would be expected to 
slow the progression of atherosclerosis. In contrast, childbirth modified cardiovascular risk 
factors, most notably a redistribution of body fat to a phenotype characterized by increased 
abdominal adiposity and marked reductions in HDL-C and apoA-I.  
There is an emerging body of literature examining the association between parity and 
cardiovascular disease. After adjustment for age, obesity, and family history of diabetes, 
increased parity was associated with a significantly increased risk of both non insulin 
dependent diabetes mellitus (NIDDM) (OR 1.16 per pregnancy) and impaired glucose 
tolerance (OR 1.10 per pregnancy) (Kritz-Silverstein et al., 1989). 
Most of the studies on the association between parity and coronary heart disease have 
included only women. However, comparisons between men and women distinguish whether 
the mechanisms for the association between parity and atherosclerosis involve biological 
processes related to pregnancy or socioeconomic or lifestyle factors that are related to family 
size and child-rearing. It has been reported that increasing parity is associated with carotid 
atherosclerosis in women but not in men among a population with at least one risk factor for 
cardiovascular disease (Lawlor et al., 2003; Skilton et al., 2009; Skilton et al., 2010). 
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Lifestyle risk factors associated with child-rearing lead to obesity and result in increased 
coronary heart diseass in both sexes but biological responses of pregnancy may have 
additional adverse effects in women (Lawlor et al., 2003).  
It is suggested that the association between childbirth and concurrent changes in IMT may 
be independent of traditional cardiovascular risk factors (Skilton et al., 2010). However, 
another study described no association between parity and either IMT or presence of 
plaques after adjustment for age in a population based cohort of 746 Finnish women 
(Kharazmi et al., 2007). The causality of the link between parity and early atherosclerosis is 
not concluded. 
6.2 Pregnancy loss 
Women who suffered one or more pregnancy losses have had pregnancies of shorter 
duration than usual and consequently they have received less/shorter estrogen exposure 
during pregnancy. The protective effect of estrogen, therefore, is potentially less than in the 
case of a full-term pregnancy (Kleijn & Schouw, 1999). However, it is more likely that 
cardiovascular disease risk in women with history of RPL may reflect common 
determinants, such as thrombophilic genetic defects, antiphospholipid antibodies, and 
endocrinological or metabolic disorders. 
Women with subclinical cardiovascular disease could have a higher risk of pregnancy loss 
and cardiovascular events later in life. There have been various reports on association 
between pregnancy loss and coronary heart disease risk or pregnancy loss and stroke risk, 
which are inconclusive (de Kleijn & Schouw, 1999; La Vecchia et al., 1987; Smith et al, 2001). 
It has been reported that a history of any spontaneous loss of early pregnancy before the 
first live birth was associated with an increased risk of ischemic heart diseases (Smith et al., 
2003). The association was independent of maternal age at the time of first birth, height, 
socioeconomic deprivation, essential hypertension, and complications during the first 
pregnancy. By contrast, there was no association between therapeutic abortion and 
subsequent risk of ischemic heart diseases. Women who had experienced at least one 
spontaneous or induced abortion had either increased or similar risk of coronary heart 
disease than women who had never had an abortion (Bertuccioa et al., 2007).   
There is a report describing that abortions, either spontaneous or induced, are not related to 
myocardial infarction risk, although underreporting cannot be excluded, because some 
women do not realize that early abortion may have occurred and because induced abortion 
may not be reported (Bertuccioa et al., 2007). 
6.3 Recurrent pregnancy loss 
In women 50–74 years of age who had experienced pregnancy, history of pregnancy loss 
tended to be associated with a higher risk of myocardial infarction (age-adjusted OR 2.1), 
and the risk increased significantly with the number of pregnancy loss (age-adjusted OR 1.4) 
(Kharazmi et al., 2010). This result suggests that women who experience RPL are likely to be 
at an increased risk of vascular disease later in life. Spontaneous RPL (>3) is associated with 
about five times higher risk of myocardial infarction after full adjustment (Kharazmi et al., 
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2011). Women who experience spontaneous pregnancy loss are at a substantially higher risk 
of myocardial infarction later in life. Although women who had history of RPL (>3) tended 
to have a higher risk of stroke (adjusted OR 1.43), associations between RPL and 
cerebrovascular events including stroke are also inconclusive. 
Several studies have shown associations between acquired and inherited thrombophilias 
and both spontaneous loss of early pregnancy and ischemic heart disease (Smith et al., 2003). 
High homocysteine levels in early pregnancy are another risk factor for pregnancy loss and 
preecclampsia (Dodds, et al., 2008). Elevated levels of homocysteine in the bloodstream can 
irritate the blood vessels, which may eventually lead to hardening of the arteries, stroke or 
heart attack. 
Miscarriage can sometimes lead to infections which may also have some links with 
cardiovascular diseases (Kharazmi et al., 2011). For instance, chlamydia infection has been 
found to be associated with occurrence of miscarriage and also with atherogenesis. 
Inflammation and infection as known risk factors for cardiovascular diseases might be the 
underlying mechanisms that explain the association between miscarriage and 
cardiovascular disease. 
It is possible that the cause of pregnancy loss is related to hemodynamic factors, such as 
preeclampsia, and therefore to cardiovascular risk or disease (de Kleijn & Schouw, 1999). 
This means that the causal relationship could be reversed: women with a cardiovascular 
disease risk could have a higher risk of pregnancy loss. Occult cardiovascular, 
microvascular, or haemostatic dysfunction result in pregnancy complications during 
reproductive years and in overt cardiovascular disease later in life (Smith et al., 2003). 
6.4 Still birth 
Stillbirth is known to be associated with an increased risk of death from coronary heart 
disease, all circulatory and renal causes (Calderon-Margalit et al., 2007). A history of 
stillbirth is reported to be associated with an increased age-adjusted risk of plaque (OR 3.43), 
but it lost its statistical significance in the fully adjusted model (Kharazmi et al., 2007). 
Recent study have reported that each stillbirth increased the risk of myocardial infarction 
2.32 times after adjustment for age, smoking, alcohol consumption, body mass index, waist 
to hip ratio, physical activity, education, number of pregnancies, hypertension, 
hyperlipidaemia and diabetes mellitus (Kharazmi et al., 2011). Stillbirth is a strong sex-
specific predictor for myocardial infarction and thus should be considered as important 
indicators for cardiovascular risk factors monitoring and preventive measures (Kharazmi et 
al., 2011). 
7. Complications in women with RPL and cardiovascular diseases 
Pregnancy complications such as preeclampsia, placental abruption, preterm birth, or birth 
of an infant small for gestational age, or gestational diabetes mellitus are characteristic in 
women with RPL. Women with RPL are also at increased risk for recurrent episode of major 
depressive disorder. These complications may be associated with vascular dysfunction in 
women with RPL. 
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7.1 Preeclampsia 
Preeclampsia affects about 5–8% of all first pregnancies and is a major cause of maternal and 
fetal morbidity and mortality worldwide. Preeclampsia is associated with vascular 
dysfunction manifesting hypertension (Nakatsuka et al., 2002) and one of common 
complications observed in women with RPL even during treatment. We have reported that 
uterine, orbital, and brachial circulations are impaired in women with preeclampsia (Takata et 
al., 2002). Several studies focused on an attenuated vasodilatory response in large blood 
vessels by evaluating flow-mediated dilatation or venous occlusion plethysmography (Spaana 
et al., 2010). One study evaluated microvascular function several years after preeclampsia, 
observing a lower response to both endothelium-dependent and independent vasodilatation 
using laser Doppler imaging of the forearm 20 years after preeclampsia (Ramsay et al. 2003). 
One of the most common risk factors for stroke in pregnancy, particularly postpartum, is 
preeclampsia/eclampsia (Bushnell & Chireau, 2011). A history of preeclampsia during 
pregnancy lead to an increased risk of stroke later in life (Bellamy et al, 2007). Biomarkers of 
endothelial dysfunction such as intercellular adhesion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1) are known to be elevated in women preeclampsia. 
Women with a history of preeclampsia are more likely to have higher insulin levels 
compared to controls. 
Although the symptoms of preeclampsia typically regress within a few days post partum, 
impaired vascular dilatation is still present several years after preeclampsia, suggesting 
persistent endothelial dysfunction, which may contribute to the development of 
cardiovascular disease in these women (Spaana et al., 2010). A recent large meta-analysis 
found that women with a history of preeclampsia have approximately double the risk for 
subsequent ischemic heart disease, stroke, and venous thromboembolic events over the 5 to 
15 years after pregnancy (Moska, 2011). Preeclampsia, particularly in association with 
preterm delivery, has been identified as a risk factor for myocardial infarction and mortality 
from cardiovascular disease later in life (James et al., 2006). 
As described in the meta-analysis and other longitudinal studies, hypertension is the risk 
factor for cerebrovascular disease that women with a history of preeclampsia and 
gestational hypertension are most likely to develop (Bellamy et al, 2007). 
7.2 Anxiety and depression 
Other factors, which are prevalent among women with RPL and may make special 
contributions to cardiovascular disease risk, include anxiety, depression, and other 
psychosocial risk factors (Blackmore et al., 2011). 
Anxiety, which is often observed in women with RPL, is also suggested to be an 
independent predictor of adverse cardiovascular events (Olafiranye et al., 2011). Individuals 
with high levels of anxiety are at increased risk of coronary heart disease, congestive heart 
failure, stroke, fatal ventricular arrhythmias, and sudden cardiac death. Anxiety following a 
major cardiac event can impede recovery, and is associated with a higher morbidity and 
mortality.  
Risk for an episode of major depressive disorder among miscarrying women in the 6 
months following loss is compared with the 6-month risk among community women who 
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have not been pregnant in the preceding year (Neugebauer et al., 1997). Among miscarrying 
women, 10.9% experience an episode of major depressive disorder, compared with 4.3% of 
community women. The overall relative risk (RR) for an episode of major depressive 
disorder for miscarrying women is 2.5 and is substantially higher for childless women (RR 
5.0) than for women with children (RR 1.3). 
Midlife women are particularly vulnerable to depressive mood; the changing hormonal 
milieu during the menopausal transition contributes to increased prevalence of depressive 
symptoms and to the worsening of the cardiovascular disease profile (Janssen et al., 2011). 
Among miscarrying women with a history of major depressive disorder, 54% experience a 
recurrence later in life. 
Symptoms of depression and major depressive disorder have been identified as potential 
risk factors for coronary heart disease (Janssen et al., 2011). Longitudinal studies have 
consistently shown that persons with high levels of depressive symptoms, or with a history 
of major depressive disorders, are more likely to have clinical coronary events than persons 
without depression. Major depression and depressive symptoms are associated with 
cardiovascular disease, but the impact of depression on early atherogenesis is less well 
known (Janssen et al., 2011). Anxiety and/or depression may be a risk factor for 
cardiovascular diseases in women with RPL. 
8. Vascular dysfunction in children of women with PRL 
Previous studies suggested that the atherogenic process in humans has already started 
during fetal development (Napoli et al, 1997). Intrauterine exposure to maternal 
atherosclerotic risk factors may increases the susceptibility to atherosclerosis in adult life 
(Alkemade et al., 2007). In a morphometric postmortem analysis of atherosclerosis in fetuses 
and children (Fate of Early Lesions in Children Study), it is demonstrated that specifically 
maternal hypercholesterolemia is associated with a higher incidence of atherosclerotic 
lesions during the fetal period and a faster progression of these atherosclerotic lesions after 
birth even under conditions of normocholesterolemia in the offspring (Napoli et al, 1999). 
8.1 Perinatal arterial ischemic stroke (PAS) 
Perinatal arterial ischemic stroke (PAS), defined as a thromboembolic event occurring before 
age 28 days, is an increasingly recognized cause of neurological disabilities such as cerebral 
palsy, epilepsy, and cognitive abnormalities (Lee et al., 2005). PAS occurs at a frequency of 
1/1600 to 1/5000 live births (Chabriera et al., 2010). Previous fetal loss, first pregnancy, 
primiparity, twin-gestation, cesarean and traumatic delivery, neonatal distress, male sex and 
premature rupture of membranes in PAS were statistically more common than in the 
general population (Chabriera et al., 2010). 
PAS may result from thrombosis of intracranial vessels or from embolism from another site 
such as extracranial vessels, heart, umbilical vein, or placenta (Nelson, 2007). Although the 
site of origin is usually not clearly established, it is suspected that the fetal side of the 
placenta may often be the source. In addition to cerebral infarction, thrombosis in other 
sites, including kidney, heart, aorta, and limb arteries, is more common in neonates than at 
other times in childhood. 
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Antiphospholipid antibodies in women RPL may pass from mother to child via the placenta, 
can alter the placenta itself and may be a risk for PAS. The inherited thrombophilias both in 
mothers and fetuses may cause RPL and PAS in neonates (Nelson, 2007). It seems likely that 
maternal and perhaps infant thrombophilias can lead to complications of pregnancy, such as 
RPL, preeclampsia, placental abruption, placental vasculopathy, and fetal growth 
restriction, which are in turn risk factors for neonatal encephalopathy, stroke, or cerebral 
palsy (Nelson, 2007). 
8.2 Genetic risk factors 
Complications of pregnancy such as preeclampsia, which are observed in untreated and 
treated women with PRL, link to low birth weight. Previous studies have shown an 
association between an individual's birth weight and his or her subsequent risk of ischemic 
heart disease, hypertension, and diabetes mellitus (Hübinettea et al., 2001). Barker and 
colleagues have postulated that fetal adaptation to inadequate intrauterine nutrition, due to 
poor maternal diet or placental dysfunction, results in physiological programming of a 
“thrifty phenotype”, which increases the risk of hypertension and ischemic heart disease in 
later life (Barker et al., 1989).  
An alternative hypothesis is that common genetic factors predispose to fetal growth 
restriction, preterm birth, and ischemic heart diseases. Common genetic risk factors might 
explain the link between birthweight and risk of ischemic heart disease in both the mother 
and the child (Smith et al., 2001). A genetic link would be consistent with the much stronger 
association between birthweight and ischemic heart disease in the mother (11-fold) (Smith et 
al., 2001) than in the offspring (1.5–2.0-fold) (Barker et al., 1989). Maternal genes might 
modulate fetal growth both by affecting the intrauterine environment, for instance by effects 
on uterine blood flow, and by inheritance of genes from the mother that regulate fetal 
growth directly. 
Epidemiological studies also provide evidence for common genetic links. Fathers of low-
birthweight babies are at increased risk of coronary heart disease, hypertension, and 
diabetes (Smith et al., 2001). Children and their mothers, who experienced RPL, may have 
common genetic factors linked to cardiovascular diseases. 
9. Treatment of pregnancy loss and prevention of cardiovascular diseases 
Currently, low-dose aspirin treatment is used as an effective therapy for women with RPL 
associated with anti-phospholipid antibodies (Coulam et al., 1997). It has been reported that 
low-dose aspirin is effective in improving implantation and pregnancy rates in the IVF 
programme (Rubinstein et al., 1999). Two trials demonstrated that women without 
hereditary thrombophilia and at least three unexplained consecutive losses randomized to 
prophylactic low molecular weight heparin had higher live birth rates than those assigned 
to placebo or no treatment (Bates, 2010). 
Antiphospholipid antibodies are more common in patients with thrombosis but a causal 
association is unproven and the clinical relevance of transient or low titer antiphospholipid 
antibodies remains uncertain (Lim et al., 2006). In patients with APS, moderate-intensity 
warfarin is effective for preventing recurrent venous thrombosis and perhaps also arterial 
thrombosis. Aspirin appears to be as effective as moderate-intensity warfarin for preventing 
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recurrent stroke in patients with prior stroke and a single positive test result for 
antiphospholipid antibody. Many patients with myocardial infarction and antiphospholipid 
antibodies are treated by warfarin. 
The relationship between preeclampsia and stroke involves shared risk factors for both 
disorders, including chronic endothelial dysfunction and increased risk for long-term 
hypertension following preeclampsia, one of the major risk factors for stroke (Bushnell & 
Chireau, 2010). Thrombophilic conditions and Vitamin D deficiency (Grant, 2009) has 
emerged as an important potentially modifiable risk factor for both preeclampsia and 
stroke. These overlaps provide insights into underlying pathophysiology and potential 
preventive strategies for both preeclampsia and stroke. For example, aspirin or Vitamin D 
may prevent both disorders. 
Early changes in vascular function are detected in mildly-hypertensive women with PCOS 
(Sasaki et al., 2011). All women diagnosed with PCOS are not likely to share the same 
cardiovascular risk profiles and increased mortality and morbidity rates from 
cardiovascular disease in the PCOS population. However, lifestyle intervention such as diet 
and exercise should be the first-line of treatment in women with PCOS, particularly if they 
are hypertensive or overweight.  
It is unlikely to treat all young women with aspirin following the occurrence of PRL without 
any other risk factors. Pharmacological therapies for hypertension, insulin resistance, or 
dyslipidemia are also available but should be tailored on an individual basis. It is important 
to evaluate arterial stiffness to identify women at early risk of cardiovascular disease and 
stroke and ultimately assess the risks and benefits of various prevention approaches. 
10. Conclusion 
Women who experienced RPL are at a substantially higher risk of vascular dysfunction, 
which leads to coronary heart disease, stroke, or VTE later in life. Reproductive history of 
obstetrical complications associated with RPL such as preeclampsia, premature delivery, 
fetal growth restriction, placental abruption, and gestational diabetes mellitus could be 
considered a “failed stress test,” possibly unmasking early or preexisting vascular 
dysfunction and vascular or metabolic diseases. Therefore, these women should be carefully 
monitored and controlled. Healthcare professionals who meet women for the first time later 
in their lives should take a careful and detailed history of RPL and characteristic pregnancy 
complications.  
Further studies will provide more information on association between PRL and vascular 
dysfunction, effective treatment for both women with PRL and their fetuses. 
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